Table 2 Characteristics of CMV+ participants.
HIV+ Subgroups | ||||||
|---|---|---|---|---|---|---|
CMV+ Uninfected controls (n = 13) | CMV+ HIV+-Infected ART-Treated (n = 36) | p-value1 | CMV+ Immuno- concordant (n = 21) | CMV+ Immuno- discordant (n = 15) | p-value2 | |
Gender (male); n (%) | 7 (54) | 30 (86) | 0.048 | 17 (81) | 14 (93.3) | 0.38 |
Age (years); Median [IQR] | 46 [41–54] | 49 [48–54] | 0.078 | 49 [48–54] | 50 [48–54] | 0.63 |
Absolute CD4+ T-cell count (cells/µL); Median [IQR] | 643 [542–823] | 451 [257–963] | 0.38 | 888 [661–1225] | 251 [166–351] | <0.0001 |
Absolute CD8+ T-cell count (cells/µL); Median [IQR] | 344 [298–366] | 668 [409–906] | <0.0001 | 753 [618–1333] | 398 [333–654] | 0.0014 |
CD4+ Nadir (cells/µL); Median [IQR] | 116 [51–188] | 163 [65–282] | 61 [20–134] | 0.01 | ||
Time since HIV diagnosis (years); Median [IQR] | 22 [18–29] | 22 [18–28] | 26 [19–22] | 0.46 | ||
Time on ART (years); Median [IQR] | 18 [15–24] | 17 [15–20] | 20 [12–24] | 0.9 | ||
HCV co-infection; n (%) | 14 [39] | 8 (38) | 6 (40) | 1 | ||
